Exciting earnings growth prospects with new contract manufacturing activity should provide the boost for the share price of this pharmaceutical maker in 2004. Analysts said Duopharma had recently started production of Methadone, which is used to treat hard drug addiction. This holds huge earnings enhancement potential, even possibly doubling the group's existing revenue, if the drug is adopted as standard treatment at rehabilitation centres in the country. Duopharma is also believed to be bidding for contracts to supply pharmaceutical products to Papua New Guinea. It is currently the largest maker of small volume injectables in Malaysia.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
